Symbols

FRES(Delisted)

Fresh2 Group·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About FRES

Fresh2 Group Limited

A biotechnology company focused on early cancer screening and detection

Industry

Established Date

Listing Date

01/30/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

fresh2.co

Security Type

Depository Receipts (Ordinary Shares)

Office address

650 5TH AVE STE 2416, NEW YORK, NY 10019-6108, United States

Business

Cancer Screening and Detection Tests Using Own CDA Technology

Introduction

Fresh2 Group Limited was incorporated in the British Virgin Islands in January 2010. The Company is a biotechnology company focused on early cancer screening and detection. The company sells a multi-cancer screening and detection test technology using their innovative patented CDA technology and patented CDA equipment. In addition to early cancer screening and detection, CDA technology has shown potential to help physicians diagnose and predict recurrence.

Company Financials

EPS

FRES has released its 2021 Q4 earnings. EPS was reported at -0.36, versus the expected 0, missing expectations. The chart below visualizes how FRES has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

FRES has released its 2022 Q4 earnings report, with revenue of 63.36K, reflecting a YoY change of -90.62%, and net profit of -4.71M, showing a YoY change of 3.68%. The Sankey diagram below clearly presents FRES's revenue sources and cost distribution.